Compare · QNCX vs RVMD
QNCX vs RVMD
Side-by-side comparison of Quince Therapeutics Inc. (QNCX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QNCX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $31.79B, about 2010.8x QNCX ($15.8M).
- Over the past year, QNCX is down 91.7% and RVMD is up 256.3% - RVMD leads by 348.0 points.
- QNCX has been more active in the news (6 items in the past 4 weeks vs 5 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 3 for QNCX).
- Company
- Quince Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $0.99-1.79%
- $149.62+0.76%
- Market cap
- $15.8M
- $31.79B
- 1M return
- -23.70%
- +5.48%
- 1Y return
- -91.66%
- +256.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 3
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest QNCX
- SEC Form 8-K filed by Quince Therapeutics Inc.
- Amendment: Quince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
- Quince Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
- Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
- Amendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.
- SEC Form 10-Q filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form DEFA14A filed by Quince Therapeutics Inc.
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress